| Name | Title | Contact Details |
|---|---|---|
Abhinav Shukla |
Chief Technical Officer | Profile |
Tetra Bio-Pharma is a multi subsidiary publicly traded company engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Our lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials in solid tumor and hematologic indications. Our pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor, currently in preclinical development.
We focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.
Simcha Therapeutics uses directed evolution to engineer novel cytokines designed to unlock the precision and power of the immune system.
Terumo Heart, Inc. is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.